Figure 4. Prevalence of nonsilent mutations in CD70, TMSB4X, B2M, DTX1, UBE2A, and LYN in an extended cohort of DLBCL patients (n = 136). CD70 was the most frequent mutation target in the present cohort. TMSB4X and LYN are novel mutation targets in DLBCL.
Figure 4

Prevalence of nonsilent mutations in CD70, TMSB4X, B2M, DTX1, UBE2A, and LYN in an extended cohort of DLBCL patients (n = 136).CD70 was the most frequent mutation target in the present cohort. TMSB4X and LYN are novel mutation targets in DLBCL.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal